Latest:
FDA Approves Third Pair of Denosumab Biosimilars
The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.
© 2025 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Authors
Jessica Mourani, PharmD
Jessica Mourani, PharmD, is Director of Clinical Outcomes for CPS Solutions.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Lindsey Mulrooney
Latest:
Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections
Julie M. Reed, the executive director of the Biosimilars Forum, dives into the efforts that the Forum is taking to ensure that FDA can catch up on their inspections backlog and get biosimilar approvals back on track.
Denise Myshko
Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com
Latest:
CVS Caremark Switches Up Biosimilar Coverage in 2024
As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Kathy Oubre, MS
Kathy W. Oubre, MS, is the Chief Operating Officer for Pontchartrain Cancer Center with locations in Covington and Hammond, Louisiana. In this role, she provides non-clinical leadership for all aspects of the practice, including financial counseling, policy/procedure development, revenue cycle management, advanced care planning, survivorship care and clinical trials.
Latest:
Biosimilars and Employers: Strategies for Success
The author, who is CEO of Pontchartrain Cancer Center, discusses how biosimilars can be part of a strategy for delivering high-quality care while achieving savings.
Sabina Alikhanov Palmieri, PharmD
Sabina Alikhanov Palmieri, PharmD, is a clinical pharmacy specialist with the Community Health Network of Connecticut.
Latest:
Updates on the Use of Biosimilars for Pediatric Patients With Rheumatic Disease
Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.
Joseph Park, PhD
Joseph Park, PhD, is the senior manager of regulatory strategy and policy at Samsung Bioepis. Park obtained his PhD from the Korea Advanced Institute of Science and Technology.
Latest:
Confusion Persists Around the Interchangeability Designation for Biosimilars
The legal and common uses of “interchangeability” continue to be conflated.
Lana Pine
Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Latest:
Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.
Advertisement
Advertisement